Discussion  by unknown
with failure of the valves. Several of these, including valve
type, preservation times, blood type, and HLA-DR mis-
match, are modifiable and thus can be used to improve
clinical results.
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Discussion
Dr David R. Clarke (Denver, Colo). Congratulations to Dr
Baskett and his coauthors are certainly in order for an excellent
clinical study and presentation.
This study clearly puts yet another nail in the coffin of the
theory that cryopreserved allografts do not elicit an immune re-
sponse. It also goes further and irrefutably links ABO and HLA
incompatibility to graft failure determined by the need for reop-
eration or echocardiographic evidence of progressive regurgitation
or significant stenosis. Two other risk factors identified could also
be associated with an immune phenomenon: Use of an aortic
homograft and shorter warm ischemic time could presumably lead
to the implantation of a higher antigenic load. Are there other
possible explanations for the appearance of these risk factors?
Dr Baskett. It is a hard group of patients to look at, as I know
you are well aware. There is so much we do not know about how
the preservation affects the valves. I think some of the clinical
factors, such as the diagnosis of pulmonary atresia, which often
goes along with peripheral pulmonary stenosis, probably unmask
failure sooner than you may see in a patient, for example, with a
Ross procedure (in which there is not the same need for a com-
petent valve). But as you point out, there seems to be a consistent
association among several factors that are known to increase the
antigenic load and valve failure. This seems to keep coming
through in everybody’s work.
Dr Clarke. You also have identified age at operation as a risk
factor that has been identified in previous studies. In previous
studies, it seems that stenosis in younger patients was very com-
mon. Did you find a difference in the failure mode related to the
age of the patient at implantation?
Dr Baskett. That is a very good question. We did not look
specifically at that when we were constructing our statistical mod-
els. The different variables presented and how one chooses to
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present them, including age and so forth, affects this. Statistically,
there is a lot of interaction with age and weight, and so forth.
Anecdotally, yes, the younger patients do tend to develop stenosis,
but I do not have specific data to prove that.
Dr Clarke. You have not referred to any technical consider-
ations specifically. Was operative technique important in any of
your patients, in terms of contributing to the failure of the valve?
Dr Baskett. People have looked before at whether proximal
extensions with Dacron or autologous pericardium affects failure.
We had only 4 patients who had a Dacron graft, and that was early
on in the experience, so there was not enough variability to look at
that. We chose instead to use primary diagnosis as a way of getting
at operative technique.
Dr Clarke. I thank you once again for a superb presentation of
an excellent study and for providing further support for the use of
a minimally antigenic valve conduit in the pediatric population. I
also thank the association for the privilege of discussing this work.
Dr John Hawkins (Salt Lake City, Utah). This has been an
excellent presentation of data showing that the failure of cryopre-
served allografts is multifactorial. I have just 1 question about
ABO incompatibility. There have been numerous studies showing
(in a multifactorial analysis similar to yours) that ABO mismatch
is actually not important in valve failure and then a couple of
studies that have shown it is important. A recent article also
demonstrated that these ABO antigens are poorly expressed, if at
all expressed, on the endothelium of cryopreserved allografts.
Have you performed any analysis of actual ABO receptors on the
endothelium of these cryopreserved allografts using your preser-
vation method?
Dr Baskett. Thank you for your question. Certainly the liter-
ature is very confusing in terms of the different variables. Part of
this is because most of the literature is from Europe, where they
tend to use the so-called fresh or homovital valves, which are
stored at 4° for approximately 1 month and then used. Clearly,
these are very different valves compared with cryopreserved
valves (which we are looking at), so some studies will say ABO is
not important. Also, depending on what you are looking at, most
studies include adults, and clearly the response in adults and
children is completely different. We have not looked specifically at
explanted valves; we did a few years ago but did not perform any
immunohistochemical staining on them. We have performed quite
a bit of work in the laboratory in the rat model looking at just that
sort of thing. It also depends on the data you have. We are
fortunate in that we have quite detailed data on all the valves,
particularly the preservation data. I believe when you have so
many variables that you can put in and account for, you are going
to see different things coming out. Some of the bigger studies have
had only 3 or 4 different variables, so certain things jump out and
overwhelm other variables that one may not have the data to
support. Looking at the literature, I find that it is a very muddy
field.
Dr Andrew S. Wechsler (Philadelphia, Pa). I have a technical
question to help me understand your data a little bit better. How
did you perform your analysis accounting for the fact that there
were only approximately half the valves for which you had histo-
compatibility data available? When you performed your analysis,
did you include data from all of the valves with missing data from
the valves in which you did not have a tissue match, or did you
look only at the valves in which you had the tissue matching and
not analyze the other valves? That may have influenced the as-
sessment you performed.
Dr Baskett. I only included the HLA subset, so there were 47
that had HLA, and I removed the other valves. So it is a suba-
nalysis, and obviously the confidence intervals are much bigger
and the numbers smaller.
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